Liquidia (NASDAQ:LQDA) CEO Sells $1,037,500.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $41.50, for a total value of $1,037,500.00. Following the transaction, the chief executive officer directly owned 1,298,095 shares of the company’s stock, valued at $53,870,942.50. This represents a 1.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total transaction of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total transaction of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total transaction of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Stock Up 6.5%

Shares of LQDA traded up $3.47 on Tuesday, hitting $56.60. 3,925,751 shares of the stock traded hands, compared to its average volume of 1,708,042. Liquidia Corporation has a one year low of $11.85 and a one year high of $57.00. The company has a market capitalization of $5.03 billion, a PE ratio of -68.19 and a beta of 0.41. The business has a 50 day simple moving average of $37.66 and a 200 day simple moving average of $35.04. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.Liquidia’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, equities analysts forecast that Liquidia Corporation will post 1.75 earnings per share for the current fiscal year.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported first-quarter EPS of $0.52, well above estimates, and revenue of $132.87 million versus expectations of $119.44 million, driven by strong YUTREPIA demand. Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: YUTREPIA net product sales rose about 44% sequentially, and the company said it has now posted a third consecutive profitable quarter, reinforcing the launch momentum. Liquidia targets at least $1B net revenue in 2027 as Yutrepia Q1 net product sales rise 44% sequentially
• Positive Sentiment: Needham raised its price target to $70 and BTIG lifted its target to $59, signaling that analysts see further upside after the earnings report. Liquidia (NASDAQ:LQDA) Price Target Raised to $70.00 at Needham & Company LLC Liquidia (NASDAQ:LQDA) Given New $59.00 Price Target at BTIG Research
• Neutral Sentiment: Several recap articles highlighted the stock’s surge to an all-time high and strong healthcare-sector momentum, but these pieces mainly reflect the same earnings-driven move rather than new company-specific news. Nasdaq Index Watch: Liquidia’s Healthcare Surge Liquidia (LQDA) Hits All-Time High as Yutrepia Drives Swing to Profits
• Negative Sentiment: One Seeking Alpha note argued the rally may be approaching a ceiling, warning that further market-share gains could be limited and that the valuation already assumes very strong future growth. Liquidia: Yutrepia’s Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Liquidia from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday. Oppenheimer increased their price target on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a report on Thursday, March 12th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, Needham & Company LLC raised their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.33.

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the fourth quarter valued at about $25,000. NewEdge Advisors LLC bought a new position in shares of Liquidia in the second quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia during the 3rd quarter valued at approximately $34,000. Finally, Covestor Ltd raised its stake in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).